Hongene Biotech Corporation, founded in 1998, is one of the earliest entrants in the nucleic acid industry. The company offers a vertically integrated platform supporting development and production of RNA and oligonucleotide-based therapeutics. With over 1,600 professionals, including 400 R&D scientists, Hongene services span from small-scale custom synthesis to large-scale GMP manufacturing, ensuring high-quality and timely delivery for global biotech and pharmaceutical partners

Key Products & Services

Raw Material Supply

Phosphoramidites (58 tonnes/year) and nucleoside triphosphates (54,000 L/year)

Other nucleic acid building blocks and reagents

Oligonucleotide Manufacturing

Custom synthesis including siRNA, sgRNA, ASOs, PMOs, PNAs, GalNAc conjugates, aptamers

mRNA CDMO Services

In-house GMP production of mRNA therapeutics and vaccines

Plasmid DNA production, IVT, cap analogs, enzymes, LNP devices, formulation, fill-finish

Diagnostics Materials

Phosphoramidites, nucleotides, dyes, quenchers, and reagent kits tailored for diagnostic applications

Contract Development & Manufacturing (CDMO)

End-to-end service from discovery through to commercial launch

Scalable infrastructure, GMP and ISO 9001 certified sites

Hongene Biotech’s comprehensive platform—from raw materials and custom oligos to GMP-grade mRNA and CDMO services—positions it as a trusted partner in the nucleic acid field. With its scale, quality systems, and global expertise, Hongene supports innovators in translating RNA science into therapeutic reality.